查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2021658

个人化癌症治疗和免疫疗法市场预测——治疗方法、生物标记、癌症类型、技术、最终用户和地区分類的全球分析——2034年

Personalized Oncology & Immunotherapy Market Forecasts to 2034 - Global Analysis By Therapy Type, Biomarker, Cancer Type, Technology, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3个工作天内

价格

全球个人化癌症治疗和免疫疗法市场预计到 2026 年将达到 1800 亿美元，并在预测期内以 11% 的复合年增长率增长，到 2034 年达到 4200 亿美元。

个人化癌症治疗和免疫疗法根据每位患者的基因谱、肿瘤特征和免疫系统反应来优化癌症治疗。这种方法包括标靶治疗、免疫查核点抑制剂和细胞疗法，旨在增强人体对癌症的抵抗力。透过专注于精准医疗，这些治疗方法能够提高疗效并减少副作用。基因组学、生物标记和诊断技术的进步正在推动该领域的创新，使癌症患者能够选择更精准的治疗方法方案并获得更好的临床疗效。

全球癌症发生率不断上升

肺癌、乳癌和大肠癌发生率的上升导致对先进治疗方法的需求激增。个人化医疗使临床医生能够根据患者的基因、分子和免疫学特征量身定制治疗方法，从而提高疗效并减少副作用。免疫疗法，包括免疫查核点抑制剂和CAR-T疗法，因其在对传统疗法抗药性的患者中展现出的持续疗效而备受关注。日益沉重的全球癌症负担正在加速对精准医疗和生物标记主导型研究的投资。医疗保健系统正将个人化癌症治疗置于优先地位，以提高存活率并降低医疗成本。

个人化医疗高成本

精准肿瘤学和免疫疗法通常涉及复杂的诊断检测、先进的生物製药和个人化治疗方法，所有这些都会推高成本。许多医疗系统，尤其是在发展中地区，由于报销机制有限，难以提供广泛的医疗服务。患者面临经济负担，自付费用成为接受治疗的一大障碍。製药公司面临着在创新和价格可负担性之间取得平衡的压力，但定价仍然是一个挑战。儘管目前正在进行研究，透过可扩展的生产和改进的诊断技术来降低成本，但价格可负担性问题仍然存在。

标靶免疫疗法的发展

基因组学和蛋白​​质组学的进步使得识别新的生物标记和治疗标靶成为可能。单株抗体、癌症疫苗和基因改造T细胞疗法等免疫疗法正日益根据患者的个别情况进行客製化。与传统化疗相比，这些方法具有更高的疗效和更低的毒性。製药公司正大力投资合作研发，以加速该领域的创新。监管机构也支持突破性治疗方法的快速核准，进一步提升了市场潜力。

与传统癌症治疗方法的竞争

由于化疗、放射线治疗和手术疗效显着且成本低廉，它们在许多地区仍然是标准的治疗方案。医生和患者可能对采用更新、更昂贵的个人化疗法犹豫不决，因为缺乏长期疗效证据。在资源匮乏的环境中，传统疗法因其价格低廉且易于取得而占据主导地位。这种对传统疗法的持续依赖可能会阻碍个人化癌症治疗方案的推广。克服这项挑战需要可靠的临床数据、成本效益研究以及提高医疗专业人员的认知。

新冠疫情的影响：

新冠疫情对个人化癌症治疗和免疫疗法市场产生了复杂的影响。一方面，临床试验和供应链的中断延缓了新治疗方法的研发和交付。许多癌症患者由于医院资源有限而被迫中断治疗。另一方面，疫情加速了数位医疗和远距远端医疗的普及，支持了远端患者监护和个人化照护的提供。製药公司透过利用分散式临床试验和数位平台继续进行研究，从而适应了这种情况。随着疫情后的復苏，肿瘤研发领域的投资重新燃起，个人化免疫疗法也重获发展动力。

在预测期内，肺癌领域预计将占据最大的市场份额。

在预测期内，肺癌领域预计将占据最大的市场份额。这是因为，随着全球癌症发生率的不断上升，肺癌已成为个人化治疗研发最为迫切的领域之一。肺癌仍然是全球癌症相关死亡的主要原因，推动了对创新治疗方法的需求。包括基于生物标誌物的标靶治疗和免疫疗法在内的个人化治疗方法正被越来越多地采用，以提高存活率。液态生物检体和基因测序等诊断技术的进步正在加速早期检测和个人化治疗。由于肺癌带来的巨大临床和经济负担，製药公司正致力于开发肺癌相关产品线。

在预测期内，癌症研究机构细分市场预计将呈现最高的复合年增长率。

在预测期内，受全球癌症发病率上升以及由此产生的对个人化医疗领域先进研发和创新需求的推动，癌症研究机构预计将呈现最高的成长率。研究机构在生物标记发现、免疫疗法开发和精准诊断方面主导。与製药公司和政府机构的合作正在加速临床试验的发展。研究机构在培养肿瘤学家和传播个人化医疗方法方面也发挥着至关重要的作用。随着癌症发生率的上升，研究机构将继续处于创新前沿，并推动快速成长。

市占率最大的地区：

在预测期内，北美预计将占据最大的市场份额，这主要得益于其先进的医疗基础设施和全球癌症发病率的上升，推动了对个人化癌症治疗方案日益增长的需求。美国在精准医疗的推广应用方面处于主导地位，这得益于其强大的研发投入和优惠的健保政策。该地区聚集了许多大型製药公司和研究机构，推动创新发展。美国食品药物管理局（FDA）等监管机构对突破性治疗方法提供快速核准，进一步促进了精准医疗的普及。在持续创新和强劲的医疗保健支出支持下，该地区的领先地位预计将继续保持。

复合年增长率最高的地区：

在预测期内，亚太地区预计将呈现最高的复合年增长率，这主要得益于医疗保健的快速数位化以及全球癌症发病率的上升，尤其是在新兴经济体。中国、印度和日本等国的癌症发生率不断上升，使得精准医疗的需求日益迫切。各国政府正在加大对肿瘤基础设施的投入，并支持临床研究工作。本地研究机构与全球製药公司之间的合作日益密切，加速了创新进程。可支配收入的增加和医疗服务可近性的提高，促使更多患者接受先进治疗方法。此外，该地区也受益于人们对精准医疗和免疫疗法日益增长的关注。

免费客製化服务：

所有购买此报告的客户均可享受以下免费自订选项之一：

  • 企业概况
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 对主要企业进行SWOT分析（最多3家公司）
  • 区域划分
    • 应客户要求，我们提供主要国家和地区的市场估算和预测，以及复合年增长率（註：需进行可行性检查）。
  • 竞争性标竿分析
    • 根据产品系列、地理覆盖范围和策略联盟对主要企业进行基准分析。

目录

第一章执行摘要

  • 市场概览及主要亮点
  • 驱动因素、挑战与机会
  • 竞争格局概述
  • 战略洞察与建议

第二章：研究框架

  • 研究目标和范围
  • 相关人员分析
  • 研究假设和限制
  • 调查方法

第三章 市场动态与趋势分析

  • 市场定义与结构
  • 主要市场驱动因素
  • 市场限制与挑战
  • 投资成长机会和重点领域
  • 产业威胁与风险评估
  • 技术与创新展望
  • 新兴市场/高成长市场
  • 监管和政策环境
  • 新冠疫情的影响及復苏前景

第四章：竞争环境与策略评估

  • 波特五力分析
    • 供应商的议价能力
    • 买方的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争公司之间的竞争
  • 主要企业市占率分析
  • 产品基准评效和效能比较

第五章 全球个人化癌症治疗与免疫疗法市场：依治疗方法

  • 免疫查核点抑制剂
  • CAR-T细胞疗法
  • 癌症疫苗
  • 单株抗体
  • 标靶小分子疗法
  • 其他治疗方法

第六章 全球个人化癌症治疗与免疫治疗市场：依生物标记划分

  • 基因生物标誌物
  • 蛋白质体学生物标誌物
  • 肿瘤突变负荷（TMB）
  • PD-L1表达
  • 其他生物标誌物

第七章 全球个人化癌症治疗与免疫治疗市场：依癌症类型划分

  • 肺癌
  • 乳癌
  • 结肠癌
  • 黑色素瘤
  • 血癌
  • 其他癌症

第八章 全球个人化癌症治疗和免疫疗法市场：按技术划分

  • 次世代定序（NGS）
  • 基于PCR的检测
  • 流式细胞技术
  • 基因编辑技术
  • 其他技术

第九章 全球个人化癌症治疗和免疫疗法市场：按最终用户划分

  • 医院
  • 癌症研究机构
  • 专科肿瘤诊所
  • 诊断检查室
  • 其他最终用户

第十章 全球个人化癌症治疗和免疫疗法市场：按地区划分

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 比利时
    • 瑞典
    • 瑞士
    • 波兰
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 马来西亚
    • 新加坡
    • 越南
    • 其他亚太国家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥伦比亚
    • 智利
    • 秘鲁
    • 其他南美国家
  • 世界其他地区（RoW）
    • 中东
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 卡达
      • 以色列
      • 其他中东国家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲国家

第十一章 策略市场资讯

  • 工业价值网络和供应链评估
  • 空白区域和机会地图
  • 产品演进与市场生命週期分析
  • 通路、经销商和打入市场策略的评估

第十二章 产业趋势与策略倡议

  • 併购
  • 伙伴关係、联盟和合资企业
  • 新产品发布和认证
  • 扩大生产能力和投资
  • 其他策略倡议

第十三章：公司简介

  • Roche Holding AG
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Johnson & Johnson
  • AstraZeneca plc
  • Gilead Sciences Inc.
  • Amgen Inc.
  • Regeneron Pharmaceuticals
  • BeiGene Ltd.
  • Moderna Inc.
  • BioNTech SE
  • Iovance Biotherapeutics
  • Bluebird Bio Inc.
  • Kite Pharma
Product Code: SMRC35101

According to Stratistics MRC, the Global Personalized Oncology & Immunotherapy Market is accounted for $180 billion in 2026 and is expected to reach $420 billion by 2034 growing at a CAGR of 11% during the forecast period. Personalized Oncology & Immunotherapy involves tailoring cancer treatment based on an individual patient's genetic profile, tumor characteristics, and immune system response. This approach includes targeted therapies, immune checkpoint inhibitors, and cell-based treatments designed to enhance the body's ability to fight cancer. By focusing on precision medicine, these therapies improve treatment effectiveness and reduce side effects. Advances in genomics, biomarkers, and diagnostics are driving innovation in this field, enabling more accurate treatment selection and better clinical outcomes for cancer patients.

Market Dynamics:

Driver:

Rising cancer prevalence globally

Increasing incidence of cancers such as lung, breast, and colorectal is creating urgent demand for advanced treatment options. Personalized therapies allow clinicians to tailor interventions based on genetic, molecular, and immunological profiles, improving efficacy and reducing side effects. Immunotherapy approaches, including checkpoint inhibitors and CAR-T therapies, are gaining traction as they offer durable responses in patients resistant to conventional treatments. The growing burden of cancer worldwide has accelerated investments in precision medicine and biomarker-driven research. Healthcare systems are prioritizing personalized oncology to improve survival rates and reduce healthcare costs.

Restraint:

High cost of personalized treatments

Precision oncology and immunotherapy often involve complex diagnostic tests, advanced biologics, and customized treatment regimens, all of which drive up expenses. Many healthcare systems, particularly in developing regions, struggle to provide widespread access due to limited reimbursement frameworks. Patients face financial toxicity, with out-of-pocket costs becoming a barrier to adoption. Pharmaceutical companies are under pressure to balance innovation with affordability, but pricing remains a challenge. While ongoing research aims to reduce costs through scalable manufacturing and improved diagnostics, affordability issues persist.

Opportunity:

Development of targeted immunotherapies

Advances in genomics and proteomics are enabling the identification of novel biomarkers and therapeutic targets. Immunotherapies such as monoclonal antibodies, cancer vaccines, and engineered T-cell therapies are increasingly being tailored to individual patient profiles. These approaches offer improved efficacy and reduced toxicity compared to traditional chemotherapy. Pharmaceutical companies are investing heavily in R&D collaborations to accelerate innovation in this space. Regulatory agencies are also supporting fast-track approvals for breakthrough therapies, enhancing market potential.

Threat:

Competition from conventional cancer therapies

Chemotherapy, radiation, and surgery remain the standard of care in many regions due to their established efficacy and lower costs. Physicians and patients may be hesitant to adopt newer, more expensive personalized treatments without long-term evidence of superiority. In resource-constrained settings, conventional therapies continue to dominate due to affordability and accessibility. This entrenched reliance on traditional approaches can slow the uptake of personalized oncology solutions. Overcoming this threat requires robust clinical data, cost-effectiveness studies, and greater awareness among healthcare providers.

Covid-19 Impact:

The COVID-19 pandemic had a mixed impact on the personalized oncology and immunotherapy market. On one hand, disruptions in clinical trials and supply chains delayed the development and delivery of new therapies. Many cancer patients experienced treatment interruptions due to hospital resource constraints. On the other hand, the pandemic accelerated adoption of digital health and telemedicine, supporting remote patient monitoring and personalized care delivery. Pharmaceutical companies adapted by leveraging decentralized trials and digital platforms to continue research. Post-pandemic recovery has reignited investments in oncology R&D, with personalized immunotherapies regaining momentum.

The lung cancer segment is expected to be the largest during the forecast period

The lung cancer segment is expected to account for the largest market share during the forecast period as rising cancer prevalence globally has made lung cancer one of the most urgent areas for personalized treatment development. Lung cancer remains the leading cause of cancer-related deaths worldwide, driving demand for innovative therapies. Personalized approaches, including biomarker-driven targeted therapies and immunotherapies, are increasingly being adopted to improve survival rates. Advances in diagnostics such as liquid biopsies and genomic sequencing are enhancing early detection and treatment personalization. Pharmaceutical companies are focusing heavily on lung cancer pipelines due to its high clinical and economic burden.

The cancer research institutes segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the cancer research institutes segment is predicted to witness the highest growth rate due to rising cancer prevalence globally, which has intensified demand for advanced research and innovation in personalized therapies. Institutes are leading efforts in biomarker discovery, immunotherapy development, and precision diagnostics. Collaborations with pharmaceutical companies and government agencies are accelerating clinical trial activity. Research institutes also play a critical role in training oncologists and disseminating knowledge about personalized treatment approaches. As cancer prevalence rises, research institutes will remain at the forefront of innovation, driving rapid growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to advanced healthcare infrastructure and rising cancer prevalence globally, which has heightened demand for personalized oncology solutions. The U.S. leads in adoption of precision medicine, supported by strong R&D investments and favorable reimbursement policies. Major pharmaceutical companies and research institutes are headquartered in the region, driving innovation. Regulatory agencies such as the FDA provide fast-track approvals for breakthrough therapies, further boosting adoption. The region's dominance is expected to persist, supported by ongoing innovation and strong healthcare spending.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by rapid healthcare digitization and rising cancer prevalence globally, particularly in emerging economies. Countries such as China, India, and Japan are witnessing increasing cancer incidence, creating urgent demand for personalized therapies. Governments are investing in oncology infrastructure and supporting clinical research initiatives. Growing collaborations between local institutes and global pharmaceutical companies are accelerating innovation. Rising disposable incomes and improving healthcare access are expanding patient adoption of advanced treatments. The region also benefits from increasing awareness of precision medicine and immunotherapy.

Key players in the market

Some of the key players in Personalized Oncology & Immunotherapy Market include Roche Holding AG, Bristol-Myers Squibb Company, Merck & Co., Inc., Novartis AG, Pfizer Inc., Johnson & Johnson, AstraZeneca plc, Gilead Sciences Inc., Amgen Inc., Regeneron Pharmaceuticals, BeiGene Ltd., Moderna Inc., BioNTech SE, Iovance Biotherapeutics, Bluebird Bio Inc. and Kite Pharma.

Key Developments:

In March 2026, Johnson & Johnson's Janssen unit introduced a personalized immunotherapy platform combining tumor-infiltrating lymphocytes (TILs) with AI-driven patient selection. The therapy targets advanced ovarian cancer, offering tailored immune responses. J&J's innovation reinforces its commitment to precision oncology, integrating cell therapy with digital health tools for improved patient outcomes.

In February 2026, Roche advanced its personalized oncology portfolio by launching a next-generation companion diagnostic platform integrated with its immunotherapy pipeline. The system enables real-time biomarker profiling for individualized treatment selection in breast and lung cancers. Roche's expansion into AI-driven diagnostics strengthens its leadership in precision oncology, aligning with its strategy to deliver tailored immunotherapy solutions across global markets.

In June 2025, Bristol-Myers Squibb expanded its immuno-oncology franchise with FDA approval of a novel PD-1 inhibitor combination therapy for advanced melanoma. The therapy leverages biomarker-driven patient stratification, enhancing survival outcomes. BMS continues to invest in personalized immunotherapy approaches, reinforcing its competitive edge in checkpoint inhibitor markets and broadening its reach in precision cancer care.

Therapy Types Covered:

  • Immune Checkpoint Inhibitors
  • CAR-T Cell Therapy
  • Cancer Vaccines
  • Monoclonal Antibodies
  • Targeted Small Molecule Therapy
  • Other Therapy Types

Biomarkers Covered:

  • Genomic Biomarkers
  • Proteomic Biomarkers
  • Tumor Mutational Burden (TMB)
  • PD-L1 Expression
  • Other Biomarkers

Cancer Types Covered:

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Melanoma
  • Hematologic Cancers
  • Other Cancer Types

Technologies Covered:

  • Next-Generation Sequencing (NGS)
  • PCR-Based Testing
  • Flow Cytometry
  • Gene Editing Technologies
  • Other Technologies

End Users Covered:

  • Hospitals
  • Cancer Research Institutes
  • Specialty Oncology Clinics
  • Diagnostic Laboratories
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Personalized Oncology & Immunotherapy Market, By Therapy Type

  • 5.1 Immune Checkpoint Inhibitors
  • 5.2 CAR-T Cell Therapy
  • 5.3 Cancer Vaccines
  • 5.4 Monoclonal Antibodies
  • 5.5 Targeted Small Molecule Therapy
  • 5.6 Other Therapy Types

6 Global Personalized Oncology & Immunotherapy Market, By Biomarker

  • 6.1 Genomic Biomarkers
  • 6.2 Proteomic Biomarkers
  • 6.3 Tumor Mutational Burden (TMB)
  • 6.4 PD-L1 Expression
  • 6.5 Other Biomarkers

7 Global Personalized Oncology & Immunotherapy Market, By Cancer Type

  • 7.1 Lung Cancer
  • 7.2 Breast Cancer
  • 7.3 Colorectal Cancer
  • 7.4 Melanoma
  • 7.5 Hematologic Cancers
  • 7.6 Other Cancer Types

8 Global Personalized Oncology & Immunotherapy Market, By Technology

  • 8.1 Next-Generation Sequencing (NGS)
  • 8.2 PCR-Based Testing
  • 8.3 Flow Cytometry
  • 8.4 Gene Editing Technologies
  • 8.5 Other Technologies

9 Global Personalized Oncology & Immunotherapy Market, By End User

  • 9.1 Hospitals
  • 9.2 Cancer Research Institutes
  • 9.3 Specialty Oncology Clinics
  • 9.4 Diagnostic Laboratories
  • 9.5 Other End Users

10 Global Personalized Oncology & Immunotherapy Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 Roche Holding AG
  • 13.2 Bristol-Myers Squibb Company
  • 13.3 Merck & Co., Inc.
  • 13.4 Novartis AG
  • 13.5 Pfizer Inc.
  • 13.6 Johnson & Johnson
  • 13.7 AstraZeneca plc
  • 13.8 Gilead Sciences Inc.
  • 13.9 Amgen Inc.
  • 13.10 Regeneron Pharmaceuticals
  • 13.11 BeiGene Ltd.
  • 13.12 Moderna Inc.
  • 13.13 BioNTech SE
  • 13.14 Iovance Biotherapeutics
  • 13.15 Bluebird Bio Inc.
  • 13.16 Kite Pharma

List of Tables

  • Table 1 Global Personalized Oncology & Immunotherapy Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Personalized Oncology & Immunotherapy Market, By Therapy Type (2023-2034) ($MN)
  • Table 3 Global Personalized Oncology & Immunotherapy Market, By Immune Checkpoint Inhibitors (2023-2034) ($MN)
  • Table 4 Global Personalized Oncology & Immunotherapy Market, By CAR-T Cell Therapy (2023-2034) ($MN)
  • Table 5 Global Personalized Oncology & Immunotherapy Market, By Cancer Vaccines (2023-2034) ($MN)
  • Table 6 Global Personalized Oncology & Immunotherapy Market, By Monoclonal Antibodies (2023-2034) ($MN)
  • Table 7 Global Personalized Oncology & Immunotherapy Market, By Targeted Small Molecule Therapy (2023-2034) ($MN)
  • Table 8 Global Personalized Oncology & Immunotherapy Market, By Other Therapy Types (2023-2034) ($MN)
  • Table 9 Global Personalized Oncology & Immunotherapy Market, By Biomarker (2023-2034) ($MN)
  • Table 10 Global Personalized Oncology & Immunotherapy Market, By Genomic Biomarkers (2023-2034) ($MN)
  • Table 11 Global Personalized Oncology & Immunotherapy Market, By Proteomic Biomarkers (2023-2034) ($MN)
  • Table 12 Global Personalized Oncology & Immunotherapy Market, By Tumor Mutational Burden (TMB) (2023-2034) ($MN)
  • Table 13 Global Personalized Oncology & Immunotherapy Market, By PD-L1 Expression (2023-2034) ($MN)
  • Table 14 Global Personalized Oncology & Immunotherapy Market, By Other Biomarkers (2023-2034) ($MN)
  • Table 15 Global Personalized Oncology & Immunotherapy Market, By Cancer Type (2023-2034) ($MN)
  • Table 16 Global Personalized Oncology & Immunotherapy Market, By Lung Cancer (2023-2034) ($MN)
  • Table 17 Global Personalized Oncology & Immunotherapy Market, By Breast Cancer (2023-2034) ($MN)
  • Table 18 Global Personalized Oncology & Immunotherapy Market, By Colorectal Cancer (2023-2034) ($MN)
  • Table 19 Global Personalized Oncology & Immunotherapy Market, By Melanoma (2023-2034) ($MN)
  • Table 20 Global Personalized Oncology & Immunotherapy Market, By Hematologic Cancers (2023-2034) ($MN)
  • Table 21 Global Personalized Oncology & Immunotherapy Market, By Other Cancer Types (2023-2034) ($MN)
  • Table 22 Global Personalized Oncology & Immunotherapy Market, By Technology (2023-2034) ($MN)
  • Table 23 Global Personalized Oncology & Immunotherapy Market, By Next-Generation Sequencing (NGS) (2023-2034) ($MN)
  • Table 24 Global Personalized Oncology & Immunotherapy Market, By PCR-Based Testing (2023-2034) ($MN)
  • Table 25 Global Personalized Oncology & Immunotherapy Market, By Flow Cytometry (2023-2034) ($MN)
  • Table 26 Global Personalized Oncology & Immunotherapy Market, By Gene Editing Technologies (2023-2034) ($MN)
  • Table 27 Global Personalized Oncology & Immunotherapy Market, By Other Technologies (2023-2034) ($MN)
  • Table 28 Global Personalized Oncology & Immunotherapy Market, By End User (2023-2034) ($MN)
  • Table 29 Global Personalized Oncology & Immunotherapy Market, By Hospitals (2023-2034) ($MN)
  • Table 30 Global Personalized Oncology & Immunotherapy Market, By Cancer Research Institutes (2023-2034) ($MN)
  • Table 31 Global Personalized Oncology & Immunotherapy Market, By Specialty Oncology Clinics (2023-2034) ($MN)
  • Table 32 Global Personalized Oncology & Immunotherapy Market, By Diagnostic Laboratories (2023-2034) ($MN)
  • Table 33 Global Personalized Oncology & Immunotherapy Market, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.